No Data
China Antibody-B (03681) and New Brightness-B (01952) have made progress in authorized cooperation, and the new BTK inhibitor SN1011 has achieved positive results in the phase 1b/2a clinical trial interim data.
This milestone result not only recognizes the huge potential of SN1011, but also marks an important milestone achievement in the authorized cooperation agreement between China Antibody and Yunding Xinyao.
China Antibody-B (03681.HK) granted 10.0624 million share options to director Wang Shanchun.
Granolith November 11th | China Antibody-B (03681.HK) announced that on November 11, 2024, the company has granted Wang Shanchun, an executive director, 10.0624 million share options under its share purchase plan, for subscription of a total of 10.0624 million new company shares.
China antibody-B (03681): Director Liu Wenyi resigns as non-executive director
China Antibody-B (03681) announced that Liu Wenyi has resigned as a non-executive director, effective September 2024...
SINOMAB BIO-B: Interim Report 2024
Some biomedical stocks rise, Akeso (09926) rises 13.9%, institutions indicate that the sector's fundamentals are gradually bottoming out and stabilizing.
Golden Finance News | Some biomedical stocks rose, with Akeso (09926) up 13.9%, Sanpower Medical (02257) up 5.47%, China Antibody (03681) up 4.35%, GL Pharm (01672) up 4.12%, Viva Biotech (01873) up 3.45%, Wuxi AppTec (02359) up 2.6%, Wuxi Bio (02269) up 1.27%. China Post Securities expressed that the overall revenue growth rate of the biomedical sector compared to the same period last year is -1.26%, lower than Q1 growth rate, mainly due to vaccines (-32.75%), and CXO (-9.45%).
Have Insiders Sold SinoMab BioScience Shares Recently?
No Data
No Data